Second OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy Held in Shanghai, Promoting Precision Medicine of China to Go Global
Summary
In this model, diagnosis and therapy are often made appropriately based on the context of a patient’s genetic content or other molecular or cellular analysis, with medical decisions, treatments, practices, or products being tailored to the needs of the patient. At the first experts’ meeting on precision medicine strategy hosted by the Ministry of Science and Technology in 2015, it was announced that investment totaling CNY 60 billion was expected in this sector by 2030. In this summit, based on accurate detection techniques and international leading biodata analysis, OrigiMed released multiple new findings for cancer patients in China that had never been reported before. Professor Wu Yilong, one of the members in the presidium and lifetime director of Guangdong General Hospital, said that China’s precise treatment would play an increasingly important role in the international community since China has entered into an era of rapid changes and reforms in medicine. With the upcoming commercialization of China’s first checkpoint inhibitor in 2018, clinical trials should be conducted for immunotherapy and precision detection employed to select optimal biomarkers to provide effective help for more patients.